Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target< (This gene does not contain this module)

Gene: CLEC2B

Summary for CLEC2B

Gene information	Gene symbol	CLEC2B
	Ensembl ID	ENSG00000110852
	Entrez ID	9976
	Gene name	C-type lectin domain family 2 member B
	Synonyms	AICL\|CLECSF2\|HP10085
	Gene type	protein_coding
	UniProtAcc	Q92478

Top

Dataset with differentially expressed gene: CLEC2B

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE140440	DU145 and PC cell lines	Cell line	Prostate cancer	Prostate cancer	Chemotherapy	docetaxel	NA	Malignant cells	4.73482	3.69e-11
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD4+ T cells	-0.263085	7.99e-40
GSE153697	patients	Bone marrow aspirate	Acute lymphoblastic leukemia	Relapsed B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	anti-CD19 CAR-T	NA	Malignant cells	-1.25331	0.00e+00
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	CD8+ T cells	0.605796	7.31e-13
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-1.02157	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	-0.7959	0.00e+00
GSE164237	patients	Peripheral blood mononuclear cells	Melanoma	Advanced stages of melanoma	Immunotherapy	pembrolizumab	pre	CD8+ T cells	-0.286103	0.00e+00
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	0.264794	1.28e-06
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	0.462834	1.30e-22
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	-0.832626	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD8+ T cells	-0.363225	5.49e-41
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	NK cells	-0.46153	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD4+ T cells	-0.453196	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD4+ T cells	-0.339523	2.88e-02
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD8+ T cells	-0.49474	1.94e-14
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Malignant cells	-0.646373	0.00e+00

Top

Expression of CLEC2B in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to CLEC2B

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Gene symbol	Cell type with DEG	Interaction ID	Interacting pair	Gene A	Gene B	Integrin	Interacting cell type1	Interacting cell type2	Dataset	Timepoint	Condition
CLEC2B	Malignant cells	CPI-SS025C8F785	CLEC2B_KLRF1	CLEC2B	KLRF1	False	Malignant cells	NK cells	GSE153697	NA	resistant
CLEC2B	Malignant cells	CPI-SS025C8F785	CLEC2B_KLRF1	CLEC2B	KLRF1	False	Malignant cells	NK cells	GSE153697	NA	sensitive
CLEC2B	CD8+ T cells	CPI-SS025C8F785	CLEC2B_KLRF1	CLEC2B	KLRF1	False	CD4+ T cells	CD8+ T cells	GSE164551	NA	resistant
CLEC2B	CD8+ T cells	CPI-SS025C8F785	CLEC2B_KLRF1	CLEC2B	KLRF1	False	CD8+ T cells	CD8+ T cells	GSE164551	NA	resistant
CLEC2B	CD8+ T cells	CPI-SS025C8F785	CLEC2B_KLRF1	CLEC2B	KLRF1	False	CD8+ T cells	NK cells	GSE164551	NA	resistant
CLEC2B	CD8+ T cells	CPI-SS025C8F785	CLEC2B_KLRF1	CLEC2B	KLRF1	False	Mono/Macro	CD8+ T cells	GSE164551	NA	resistant
CLEC2B	CD8+ T cells	CPI-SS025C8F785	CLEC2B_KLRF1	CLEC2B	KLRF1	False	NK cells	CD8+ T cells	GSE164551	NA	resistant
CLEC2B	CD8+ T cells	CPI-SS025C8F785	CLEC2B_KLRF1	CLEC2B	KLRF1	False	CD4+ T cells	CD8+ T cells	GSE164551	NA	sensitive
CLEC2B	CD8+ T cells	CPI-SS025C8F785	CLEC2B_KLRF1	CLEC2B	KLRF1	False	CD8+ T cells	CD8+ T cells	GSE164551	NA	sensitive
CLEC2B	CD8+ T cells	CPI-SS025C8F785	CLEC2B_KLRF1	CLEC2B	KLRF1	False	CD8+ T cells	NK cells	GSE164551	NA	sensitive
CLEC2B	CD8+ T cells	CPI-SS025C8F785	CLEC2B_KLRF1	CLEC2B	KLRF1	False	Mono/Macro	CD8+ T cells	GSE164551	NA	sensitive
CLEC2B	CD8+ T cells	CPI-SS025C8F785	CLEC2B_KLRF1	CLEC2B	KLRF1	False	NK cells	CD8+ T cells	GSE164551	NA	sensitive
CLEC2B	CD4+ T cells	CPI-SS025C8F785	CLEC2B_KLRF1	CLEC2B	KLRF1	False	CD4+ T cells	NK cells	GSE169246_PacTissue	post	resistant
CLEC2B	CD4+ T cells	CPI-SS025C8F785	CLEC2B_KLRF1	CLEC2B	KLRF1	False	CD4+ T cells	NK cells	GSE169246_PacTissue	post	sensitive
CLEC2B	CD8+ T cells	CPI-SS025C8F785	CLEC2B_KLRF1	CLEC2B	KLRF1	False	CD8+ T cells	NK cells	GSE199333	post	resistant
CLEC2B	Malignant cells	CPI-SS025C8F785	CLEC2B_KLRF1	CLEC2B	KLRF1	False	Malignant cells	NK cells	GSE199333	post	resistant
CLEC2B	CD4+ T cells	CPI-SS025C8F785	CLEC2B_KLRF1	CLEC2B	KLRF1	False	CD4+ T cells	NK cells	GSE199333	post	resistant
CLEC2B	NK cells	CPI-SS025C8F785	CLEC2B_KLRF1	CLEC2B	KLRF1	False	B cells	NK cells	GSE199333	post	resistant
CLEC2B	NK cells	CPI-SS025C8F785	CLEC2B_KLRF1	CLEC2B	KLRF1	False	CD4+ T cells	NK cells	GSE199333	post	resistant
CLEC2B	NK cells	CPI-SS025C8F785	CLEC2B_KLRF1	CLEC2B	KLRF1	False	CD8+ T cells	NK cells	GSE199333	post	resistant
CLEC2B	NK cells	CPI-SS025C8F785	CLEC2B_KLRF1	CLEC2B	KLRF1	False	Malignant cells	NK cells	GSE199333	post	resistant
CLEC2B	NK cells	CPI-SS025C8F785	CLEC2B_KLRF1	CLEC2B	KLRF1	False	NK cells	NK cells	GSE199333	post	resistant
CLEC2B	CD8+ T cells	CPI-SS025C8F785	CLEC2B_KLRF1	CLEC2B	KLRF1	False	CD8+ T cells	CD8+ T cells	GSE199333	post	sensitive
CLEC2B	CD8+ T cells	CPI-SS025C8F785	CLEC2B_KLRF1	CLEC2B	KLRF1	False	CD8+ T cells	NK cells	GSE199333	post	sensitive
CLEC2B	CD8+ T cells	CPI-SS025C8F785	CLEC2B_KLRF1	CLEC2B	KLRF1	False	Malignant cells	CD8+ T cells	GSE199333	post	sensitive
CLEC2B	CD8+ T cells	CPI-SS025C8F785	CLEC2B_KLRF1	CLEC2B	KLRF1	False	NK cells	CD8+ T cells	GSE199333	post	sensitive
CLEC2B	Malignant cells	CPI-SS025C8F785	CLEC2B_KLRF1	CLEC2B	KLRF1	False	Malignant cells	CD8+ T cells	GSE199333	post	sensitive
CLEC2B	Malignant cells	CPI-SS025C8F785	CLEC2B_KLRF1	CLEC2B	KLRF1	False	Malignant cells	NK cells	GSE199333	post	sensitive
CLEC2B	CD4+ T cells	CPI-SS025C8F785	CLEC2B_KLRF1	CLEC2B	KLRF1	False	CD4+ T cells	NK cells	GSE199333	post	sensitive
CLEC2B	NK cells	CPI-SS025C8F785	CLEC2B_KLRF1	CLEC2B	KLRF1	False	CD4+ T cells	NK cells	GSE199333	post	sensitive
CLEC2B	NK cells	CPI-SS025C8F785	CLEC2B_KLRF1	CLEC2B	KLRF1	False	CD8+ T cells	NK cells	GSE199333	post	sensitive
CLEC2B	NK cells	CPI-SS025C8F785	CLEC2B_KLRF1	CLEC2B	KLRF1	False	Malignant cells	NK cells	GSE199333	post	sensitive
CLEC2B	NK cells	CPI-SS025C8F785	CLEC2B_KLRF1	CLEC2B	KLRF1	False	NK cells	CD8+ T cells	GSE199333	post	sensitive
CLEC2B	NK cells	CPI-SS025C8F785	CLEC2B_KLRF1	CLEC2B	KLRF1	False	NK cells	NK cells	GSE199333	post	sensitive
CLEC2B	Malignant cells	CPI-SS025C8F785	CLEC2B_KLRF1	CLEC2B	KLRF1	False	Malignant cells	NK cells	GSE199333	pre	resistant
CLEC2B	CD8+ T cells	CPI-SS025C8F785	CLEC2B_KLRF1	CLEC2B	KLRF1	False	CD8+ T cells	NK cells	GSE199333	pre	resistant
CLEC2B	CD4+ T cells	CPI-SS025C8F785	CLEC2B_KLRF1	CLEC2B	KLRF1	False	CD4+ T cells	NK cells	GSE199333	pre	resistant
CLEC2B	Malignant cells	CPI-SS025C8F785	CLEC2B_KLRF1	CLEC2B	KLRF1	False	Malignant cells	NK cells	GSE199333	pre	sensitive
CLEC2B	CD8+ T cells	CPI-SS025C8F785	CLEC2B_KLRF1	CLEC2B	KLRF1	False	CD8+ T cells	NK cells	GSE199333	pre	sensitive
CLEC2B	CD4+ T cells	CPI-SS025C8F785	CLEC2B_KLRF1	CLEC2B	KLRF1	False	CD4+ T cells	NK cells	GSE199333	pre	sensitive
CLEC2B	CD8+ T cells	CPI-SS025C8F785	CLEC2B_KLRF1	CLEC2B	KLRF1	False	CD8+ T cells	NK cells	GSE207422_Sin	post	resistant
CLEC2B	CD4+ T cells	CPI-SS025C8F785	CLEC2B_KLRF1	CLEC2B	KLRF1	False	CD4+ T cells	NK cells	GSE207422_Sin	post	resistant
CLEC2B	CD8+ T cells	CPI-SS025C8F785	CLEC2B_KLRF1	CLEC2B	KLRF1	False	CD8+ T cells	NK cells	GSE207422_Sin	post	sensitive
CLEC2B	CD4+ T cells	CPI-SS025C8F785	CLEC2B_KLRF1	CLEC2B	KLRF1	False	CD4+ T cells	NK cells	GSE207422_Sin	post	sensitive

Page: 1

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating CLEC2B

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
CLEC2B	hsa-miR-29b-1-5p	94.2165	NM_005127
CLEC2B	hsa-miR-2052	93.5048	NM_005127
CLEC2B	hsa-miR-4446-5p	92.1593	NM_005127
CLEC2B	hsa-miR-6832-5p	90.5535	NM_005127
CLEC2B	hsa-miR-3119	90.0899	NM_005127
CLEC2B	hsa-miR-582-5p	88.2234	NM_005127
CLEC2B	hsa-miR-299-5p	86.4448	NM_005127
CLEC2B	hsa-miR-10b-5p	83.196	NM_005127
CLEC2B	hsa-miR-10a-5p	83.196	NM_005127
CLEC2B	hsa-miR-6874-3p	82.3392	NM_005127
CLEC2B	hsa-miR-148b-5p	82.3392	NM_005127
CLEC2B	hsa-miR-561-3p	81.4848	NM_005127

Page: 1

Top

Motifs and transcription factors (TFs) regulating CLEC2B

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
CLEC2B	taipale_tf_pairs__TEAD4_HOXA13_RCATWCCNNNNNNTTTAYNNN_CAP_repr	HOXA13; TEAD4 (directAnnotation).
CLEC2B	tfdimers__MD00302	IRF7; IRF8 (directAnnotation).
CLEC2B	taipale_tf_pairs__GCM1_ETV4_RTGCGGGCGGAAGTR_CAP	ETV4; GCM1 (directAnnotation).
CLEC2B	swissregulon__hs__ETV6	ETV6 (directAnnotation).
CLEC2B	taipale_tf_pairs__ERF_FOXI1_RSCGGATGTTKWN_CAP_repr	ERF; FOXI1 (directAnnotation).
CLEC2B	taipale_tf_pairs__ETV2_HOXA2_NCCGGAAGTMATTA_CAP_repr	ETV2; HOXA2 (directAnnotation).
CLEC2B	transfac_pro__M04826	EP300 (directAnnotation).
CLEC2B	metacluster_172.23	ZBTB32; ZBTB32 (directAnnotation).
CLEC2B	metacluster_19.6	GMEB1 (directAnnotation). GMEB1 (inferredBy_Orthology).
CLEC2B	transfac_pro__M06686	PRDM9 (directAnnotation).
CLEC2B	metacluster_175.6	GRHL1; GRHL1; GRHL1; GRHL1; TFCP2 (directAnnotation).
CLEC2B	taipale_tf_pairs__HOXB13_ETV1_RSCGGAARYNNTAAAN_CAP_repr	ETV1; HOXB13 (directAnnotation).
CLEC2B	transfac_pro__M06273	ZNF766 (directAnnotation).
CLEC2B	taipale_tf_pairs__FOXO1_ETV4_RCCGGAWGTKKN_CAP	ETV4; FOXO1 (directAnnotation).
CLEC2B	taipale_tf_pairs__FOXO1_ELK1_RSCGGATGTTRTN_CAP	ELK1; FOXO1 (directAnnotation).
CLEC2B	taipale_tf_pairs__ETV2_FOXO6_RCCGGATGTTKWN_CAP	ETV2; FOXO6 (directAnnotation).
CLEC2B	taipale_tf_pairs__ETV2_FOXI1_RSCGGATGTTKW_CAP	ETV2; FOXI1 (directAnnotation).
CLEC2B	taipale_tf_pairs__GCM1_ETV1_RTRNNGGCGGAAGTN_CAP	ETV1; GCM1 (directAnnotation).
CLEC2B	transfac_pro__M04858	THAP1 (directAnnotation).
CLEC2B	metacluster_47.1	E4F1; SPDEF; SPDEF (directAnnotation).
CLEC2B	taipale_tf_pairs__FLI1_FOXI1_RCCGGATGTTKWY_CAP	FLI1; FOXI1 (directAnnotation).
CLEC2B	swissregulon__hs__SOX9	SOX9 (directAnnotation).
CLEC2B	homer__VVRRAACAATGG_Sox7	SOX7 (inferredBy_Orthology).

Page: 1

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."